Abstract
The polymorphic CYP2D6 enzyme is estimated to be responsible for the oxidation of 20-25% of all drugs in clinical use. However, genotyping for its variants is not routinely clinically available. The gene is particularly complex, with different platforms analysing different subsets of variants. GENDEP (Genome-based therapeutic drugs for depression) is a multicentre clinical trial which found an association between CYP2D6 genotype and nortriptyline concentration, but no association between CYP2D6 or CYP2C19 and response to nortriptyline. The CYP2D6 data were produced using the AmpliChip CYP450 Test, which had weaknesses, such as lack of coverage of hybrid alleles between CYP2D6 and its adjacent pseudogene (CYP2D7).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
